Literature DB >> 12696579

Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.

Masaya Takaoka1, Shinya Sehata, Takanori Maejima, Toshio Imai, Mikinori Torii, Hiroshi Satoh, Kaoru Toyosawa, Zen-yo Tanakamaru, Tamiko Adachi, Shigeru Hisada, Makoto Ueda, Hiroyuki Ogasawara, Masahiro Matsumoto, Kiyoshi Kobayashi, Mamoru Mutai, Toshimi Usui.   

Abstract

In order to evaluate a short-term carcinogenicity testing system using CB6F1 -Tg rasH2 (rasH2-Tg) mice carrying a human prototype c-Ha-ras gene, 26-week studies were conducted in 12 different facilities as a part of an International Life Science Institute Health and Environmental Science Institute (ILSI HESI) international collaborative project. In each study N-methyl-N-nitrosourea (MNU) was administered to a separate group of rasH2-Tg mice by single intraperitoneal injection (75 mg/kg) as a positive control. We herein have summarized the mortality, body weight change, and neoplastic and nonneoplastic lesions detected in these positive control groups as representative historical positive control data. Also, we performed an interlaboratory comparison of the response of rasH2-Tg mice to MNU based on the data of 11 positive control groups from these studies. Although the body weight of rasH2-Tg mice showed lower values than that of non-Tgmice during the experimental period, body weight gain in the rasH2-Tg mice was similar to that in non-Tg mice. The mortality of rasH2-Tg mice during the study period was very low, the same as for the non-Tg mice. Incidences of spontaneous alveolar/bronchiolar adenomas and splenic hemangiomas/hemangiosarcomas were also low in the rasH2-Tg mice. Nonneoplastic lesions detected in the rasH2-Tg mice were similar to those in non-Tg mice, excluding the incidence of myopathy. There were interlaboratory differences in mortality and incidence of some lesions in the MNU-treated groups. However, the causes of death were common among the 11 laboratories and almost all the MNU-treated rasH2-Tg mice developed forestomach squamous cell papillomas/carcinomas or malignant lymphomas. This suggests that there is no appreciable difference in the response of the rasH2-Tg mouse to MNU used as a positive control. Therefore, it is concluded that MNU would be an adequate positive control compound in this testing system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12696579     DOI: 10.1080/01926230390183670

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

Review 1.  The potential of organoids in toxicologic pathology: Histopathological and immunohistochemical evaluation of a mouse normal tissue-derived organoid-based carcinogenesis model.

Authors:  Rikako Ishigamori; Mie Naruse; Akihiro Hirata; Yoshiaki Maru; Yoshitaka Hippo; Toshio Imai
Journal:  J Toxicol Pathol       Date:  2022-04-22       Impact factor: 1.250

2.  Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B.

Authors:  Edward G Bridges; Jules R Selden; Shouqi Luo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

3.  Successful drug development despite adverse preclinical findings part 2: examples.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; Makoto Hayashi; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

4.  Endogenous controls of gene expression in N-methyl-N-nitrosourea-induced T-cell lymphoma in p53-deficient mice.

Authors:  Xi Wu; Susu Liu; Jianjun Lyu; Shuya Zhou; Yanwei Yang; Chenfei Wang; Wenda Gu; Qin Zuo; Baowen Li; Changfa Fan
Journal:  BMC Cancer       Date:  2017-08-14       Impact factor: 4.430

5.  Generation of a uniform thymic malignant lymphoma model with C57BL/6J p53 gene deficient mice.

Authors:  Susu Liu; Jianjun Lyu; Qianqian Li; Xi Wu; Yanwei Yang; Guitao Huo; Qingfen Zhu; Ming Guo; Yuelei Shen; Sanlong Wang; Changfa Fan
Journal:  J Toxicol Pathol       Date:  2022-09-26       Impact factor: 1.628

6.  Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model.

Authors:  Hiroyuki Kuroda; Toshiko Kinomoto; Shuji Ogawa; Mayumi Kawabe; Mayuko Suguro; Hitoshi Naraoka; Kazuhiko Takamatsu; Yuji Oishi
Journal:  J Toxicol Pathol       Date:  2017-09-21       Impact factor: 1.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.